Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
NCT05647343Phase 1Completed
- Sponsor
- Atlas Molecular Pharma
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ciclopirox in congenital erythropoietic porphyria (CEP) (5 arms), sponsored by Atlas Molecular Pharma. Primary endpoint: Incidence of adverse events at 3.5 months. Started Mar 2023; status: completed.
02
Drugs
ciclopirox
03
Conditions
congenital erythropoietic porphyria (CEP)
Beyond the preview
Go deeper on NCT05647343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647343.